Correlates of protection, antigen delivery and molecular epidemiology: Basics for designing an HIV vaccine

Vaccine

Volumn 17, Issue 13-14, 1999, Pages 1706-1710

  Wagner, Ralf ^a   Shao, Yiming ^b   Wolf, Hans ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Antigen presentation; CD8 lymphocytes; Epidemiology; Field trial; Long term nonprogressors; Preclinical studies

Indexed keywords

CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MOLECULAR CLONING; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS PARTICLE; VIRUS REPLICATION;

AIDS VACCINES; ANTIGEN PRESENTATION; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; VIRION;

EID: 0345435053     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00431-9     Document Type: Conference Paper

References (18)

1. Paul W.E. Can the immune response control HIV infection? Cell. 82:1995;177-182.
2. Wagner R, Leschonsky B, Harrer E, Paulus C, Weber C, Walker BD, Buchbinder S, Wolf H, Kalden JR, Harrer T. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized by CTL from a long term non progressor: constraints on the immune escape by targeting an epitope essentially involved in viral replication. J. Immunol. in press.
3. Harrer T., Harrer E., Kalams S.A., Barbosa P., Trocha A., Johnson R.P., Elbeik T., Feinberg M.B., Buchbinder S.P., Walker B.D. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection-breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. Journal of Immunology. 156:1996;2616-2623.
4. Emini E.A., Schleif W.A., Nunberg J.H., Conley A.J., Eda Y., Tokiyoshi S., Putney S.D., Matsushita S., Cobb K.E., Jett C.M.et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 355:1992;728-730.
5. Gheysen D., Jacobs E., de Foresta F., Thiriart C., Francotte M., Thines D., De Wilde M. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell. 59:1989;103-112.
6. Wagner R., Fliessbach H., Wanner G., Motz M., Niedrig M., Deby G., von Brunn A., Wolf H. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch. Virol. 127:1992;117-137.
7. Wagner R., Boltz T., Deml L., Modrow S., Wolf H. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. J. Gen. Virol. 74:1993;1261-1269.
8. Wagner R., Deml L., Fliessbach H., Wanner G., Wolf H. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology. 200:1994;162-175.
9. Wagner R., Deml L., Schirmbeck R., Niedrig M., Reimann J., Wolf H. Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology. 220:1996;128-140.
10. Deml L., Kratochwil G., Osterrieder N., Knuchel R., Wolf H., Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology. 235:1997;10-25.
11. Deml L., Schirmbeck R., Reimann J., Wolf H., Wagner R. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology. 235:1997;26-39.
12. Schirmbeck R., Deml L., Melber K., Wolf H., Wagner R., Reimann J. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine. 13:1995;857-865.
13. Osterrieder N., Wagner R., Brandmuller C., Schmidt P., Wolf H., Kaaden O.R. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology. 208:1995;500-510.
14. Wagner R., Deml L., Notka F., Wolf H., Schirmbeck R., Reimann J., Teeuwsen V., Heeney J. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology. 39:1996;93-103.
15. Wagner R., Teeuwsen V.J., Deml L., Notka F., Haaksma A.G., Jhagjhoorsingh S.S., Niphuis H., Wolf H., Heeney J.L. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. Virology. 245:1998;65-74.
16. HIV-1 subtypes: implications for epidemiology, pathogenicity, vaccines and diagnostics. Workshop Report from the European Commission (DG XII, INCO-DC) and the Joint United Nations Programme on HIV/AIDS. AIDS 1997, 11, pp. 17-36.
17. Salminen M.O., Koch C., Sanders Buell E., Ehrenberg P.K., Michael N.L., Carr J.K., Burke D.S., McCutchan F.E. Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology. 213:1995;80-86.
18. Graf M., Shao Y., Zhao Q., Seidl T., Kostler J., Wolf H., Wagner R. Cloning and characterization of a virtually full-length HIV type 1 genome from a subtype B′-Thai strain representing the most prevalent B-clade isolate in China. AIDS Res. Hum. Retroviruses. 14:1998;285-288.